Your browser doesn't support javascript.
loading
A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L).
Hayashi, Hidetoshi; Sugawara, Shunichi; Fukuda, Yasushi; Fujimoto, Daichi; Miura, Satoru; Ota, Keiichi; Ozawa, Yuichi; Hara, Satoshi; Tanizaki, Junko; Azuma, Koichi; Omori, Shota; Tachihara, Motoko; Nishino, Kazumi; Bessho, Akihiro; Chiba, Yasutaka; Haratani, Koji; Sakai, Kazuko; Nishio, Kazuto; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko.
Afiliación
  • Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Aoba-ku, Sendai, Miyagi, Japan.
  • Fukuda Y; Department of Respiratory Medicine, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
  • Fujimoto D; Department of Respiratory Medicine, Kobe City Medical Center General Hospital, Chuo-ku, Kobe, Hyogo, Japan.
  • Miura S; Department of Internal Medicine, Niigata Cancer Center Hospital, Chuo-ku, Niigata, Niigata, Japan.
  • Ota K; Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan.
  • Ozawa Y; Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
  • Hara S; Department of Respiratory Medicine, Itami City Hospital, Itami, Hyogo, Japan.
  • Tanizaki J; Department of Medical Oncology, Kishiwada City Hospital, Kishiwada, Osaka, Japan.
  • Azuma K; Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
  • Omori S; Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan.
  • Tachihara M; Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Hyogo, Japan.
  • Nishino K; Department of Thoracic Oncology, Osaka International Cancer Institute, Chuo-ku, Osaka, Japan.
  • Bessho A; Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Kita-ku, Okayama, Japan.
  • Chiba Y; Clinical Research Center, Kindai University Hospital, Osaka-Sayama, Osaka, Japan.
  • Haratani K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Sakai K; Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Nishio K; Department of Genome Biology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
  • Yamamoto N; Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
  • Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.
Clin Cancer Res ; 28(5): 893-902, 2022 Mar 01.
Article en En | MEDLINE | ID: mdl-34921023
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Nivolumab / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Carcinoma de Pulmón de Células no Pequeñas / Nivolumab / Neoplasias Pulmonares Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Japón